Ohio State Navbar

Research

Ongoing Studies


Ongoing Clinical Research Trials:
              
The Ohio State University Medical Center is a national leader in conducting clinical trials for prevention and treatment of various diseases, which includes diabetes. The Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Metabolism Research Center conduct research for Type 1 and Type 2 diabetes both for NIH and industry sponsored studies.              

For information on the benefits and risks of participating in a clinical research trial, please click here.

The Division of Endocrinology, Diabetes and Metabolism and the DMRC are currently enrolling in the following clinical trials. Each study has specific requirements for enrolment. If you are interested in participating in any of the studies, please contact the person listed.

Improving beta cell function in young Mexican American (Hispanic) young women with prediabetes- in Houston, TX – This study program targets young Hispanic women (18-40 years of age) with a family history of diabetes, who believe they are overweight and have or may have prediabetes. The study is conducted in Houston, TX. Contact, Evangelina Villagomez, PhD or Patricia Casillas, LVN at 346-206-8869. The program involves a 6 month behavioral and medically supervised intervention. Our program is funded by National Institutes Health, The Department of Health & Human Services and thus is free of charge. The study program duration is 4 years.

Willa Hsueh, MD, Principle Investigator of this federally funded study conducted in Houston, TX. Co-Investigators, include Kathleen Wyne, MD, David Bradley, MD and Evangelina Villagomez, PhD, who directs the study activities in Houston, TX. The Program is entitled, “Diabetes Intervention & Prevention in Young Hispanic Women with Prediabetes”. We will compare the effects of a culturally sensitive intensive lifestyle intervention program with and without liraglutide (Saxenda).

With the assistance of Drs. Rotter, Chen and Goodarzi (UCLA Co-investigators), the team aims to identify genetic biomarkers of response to a pharmacologic intervention that targets the pancreatic β-cell. These results help to a) understand mechanisms of disease, b) personalize treatment through identification of a high risk group that may be amenable to specific therapy, and c) ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and costly disease, in MA. | Learn more about this study on StudySearch

Toujeo – this study will compare Toujeo insulin to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes. Study commitment is one year with 4 visits, $20 per study visit. Contact Amber Anaya for details 614-688-6257

Pioneer – this is a study to test the efficacy and safety or oral semaglutide versus sitaglipin in patients with type 2 diabetes. Patients who are on Metformin alone, or Metformin plus a sulfonylurea will qualify for the PIONEER study. PIONEER will last about 1.5 years with a $40 reimbursement per visit.  Contact Amber Anaya for details 614-688-6257

Regenerate – a study evaluating the safety and efficacy of Obeticholic Acid in patients with NASH. Contact Amber Anaya for details 614-688-6257

Pasireotide – Patients with Cushing’s disease and treated with Pasireotide alone and in combination with other therapies will be monitored for 3 years. This is a non-interventional data collection. Please contact Ashley Mintos at 614-688-6885 if interested

Cortendo – An open label study to assess the safety and efficacy of COR-003(Ketoconazole) in patients with Endogenous Cushing’s Syndrome. Subjects will receive $40 for all completed clinic visits. Please contact Angela Howell at 614-688-3785 if interested.

Harmony Outcomes – We are looking for patients who have type 2 diabetes, a history of heart disease and an HbA1c > 7%. The study will compare weekly injections of albiglutide or placebo (an inactive substance) to find out whether people taking albiglutide have a higher or lower risk of developing cardiovascular complications (heart attack, stroke, or death from cardiovascular disease) than people who do not take albiglutide. The research study is expected to last for 3–5 years, and eligible participants will receive study medication and $50 for each study-related clinic visit. Please contact Ashley Mintos at 614-688-6885 if interested